Lupus & antiphospholipid syndrome
Multimarker profiling of immune and vascular disregulation in antiphospholipid syndrome and systemic lupus erythematosus
Authors' conclusion
The study highlights the interplay of immune, inflammatory, and endothelial dysfunction biomarkers in APS and their association with clinical manifestations.
Study context
- Population
- Patients with primary and secondary APS and SLE, and controls
- Participants
- 79 / 47 / 36 / 56
- Exposure
- Primary APS, secondary APS and SLE vs controls
- PAPSn = 79
- SAPSn = 47
- SLEn = 36
- Controln = 56reference
- Outcome
- Biomarker associations with clinical manifestations
Methodological detailsmultivariate logistic regression, principal component analysis
- Multivariate logistic regression
- Principal component analysis
Main finding
As reported in the abstract
- Non-criteria aPLs significantly elevated in all patient groups vs controls
- p < 0.001
- Correlation aPS/PT IgG with lupus anticoagulant ratio (LAR)
- r = 0.670, p < 0.001
- Correlation aβ2GPI IgG with LAR
- r = 0.625, p < 0.001
- Fetal loss model (χ21 = 16.18, p = 0.013): endoglin, OR per increase (probability raised by 45.1%)
- OR = 1.451, p = 0.040
- Fetal loss: lower ferritin independently associated
- p = 0.004
- Thrombosis model (χ21 = 19.87, p = 0.011): ferritin, OR per unit increase (probability raised by 1.5%)
- OR = 1.015
- Principal component analysis (PCA): two main factors explaining variance
- 63%
- PCA: Immunological-related factor (aCL IgG, aβ2GPI IgG, aPS/PT IgG, aCL IgA)
- 42.96%
- PCA: Prothrombotic and metabolic-related factor (aβ2GPI IgM, tissue factor, aCL IgA, inversely UIBC)
- 20.06%
Observational data: associations, not effects.
Original publication
Multimarker profiling of immune and vascular disregulation in antiphospholipid syndrome and systemic lupus erythematosus. Lupus. Published 30 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →